Bodyport is a biomarker-guided digital therapeutics company that aims to address complex chronic conditions by embedding a biomarker platform in easy-to-use devices. The devices provide comprehensive health insights at home.
Bodyport's non-invasive, biomarker-guided monitoring technology predicts heart failure events at twice the rate of conventional care, according to published clinical results. The Journal of Cardiac Failure publishes SCALE-HF 1 data evaluating the Bodyport system for monitoring heart failure events.
Bodyport and Geisinger announce a collaboration to integrate Bodyport’s Cardiac Scale and Fluid Alerts into remote heart-failure care. The initial program plans daily home monitoring for approximately 200 patients over a 12-month pilot.
Bodyport receives FDA 510(k) clearance for its Cardiac Scale, which measures indicators of heart function and fluid status during an at-home weighing step. The clearance supports the company's expansion of noninvasive remote monitoring.
Bodyport appoints Jim Pursley, president of Hinge Health, to its board of directors. The company adds his healthcare leadership experience as it prepares to expand commercialization of its remote-monitoring technology.